X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
midostaurin (64) 64
index medicus (50) 50
humans (38) 38
acute myeloid leukemia (32) 32
leukemia (29) 29
hematology (27) 27
oncology (25) 25
mutation (23) 23
flt3 (22) 22
internal tandem duplication (22) 22
pkc412 (22) 22
tyrosine kinase inhibitor (22) 22
chemotherapy (21) 21
staurosporine - analogs & derivatives (20) 20
acute myelogenous leukemia (19) 19
pharmacology & pharmacy (19) 19
leukemia, myeloid, acute - drug therapy (18) 18
midostaurin pkc412 (18) 18
acute myeloid-leukemia (17) 17
aml (17) 17
sorafenib (17) 17
tyrosine (16) 16
cancer (15) 15
hemic and lymphatic diseases (14) 14
kinases (14) 14
phase-i (13) 13
adult patients (12) 12
antineoplastic agents - therapeutic use (12) 12
fms-like tyrosine kinase 3 - genetics (12) 12
leukemia, myeloid, acute - genetics (12) 12
female (11) 11
fms-like tyrosine kinase 3 - antagonists & inhibitors (11) 11
protein kinase inhibitors - therapeutic use (11) 11
kinase inhibitor (10) 10
risk myelodysplastic syndrome (10) 10
systemic mastocytosis (10) 10
animals (9) 9
antineoplastic agents - pharmacology (9) 9
clinical trials (9) 9
imatinib (9) 9
male (9) 9
medical prognosis (9) 9
medicine & public health (9) 9
middle aged (9) 9
mutations (9) 9
myeloid leukemia (9) 9
staurosporine - therapeutic use (9) 9
wild-type (9) 9
aged (8) 8
article (8) 8
myelodysplastic syndrome (8) 8
quizartinib (8) 8
review (8) 8
staurosporine - administration & dosage (8) 8
stem-cell transplantation (8) 8
adult (7) 7
c-kit (7) 7
care and treatment (7) 7
embryonic structures (7) 7
health aspects (7) 7
hemic and immune systems (7) 7
lestaurtinib (7) 7
older patients (7) 7
patients (7) 7
prognostic-significance (7) 7
research (7) 7
therapeutic target (7) 7
activating mutation (6) 6
apoptosis (6) 6
bone marrow (6) 6
cells (6) 6
clinical trials as topic (6) 6
flt3 inhibitor (6) 6
flt3 inhibitors (6) 6
fluids and secretions (6) 6
gemtuzumab ozogamicin (6) 6
inhibitor (6) 6
mastocytosis (6) 6
medical colleges (6) 6
protein kinases (6) 6
protein-kinase-c (6) 6
proteins (6) 6
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
combination (5) 5
crenolanib (5) 5
drug administration schedule (5) 5
drug therapy (5) 5
gene mutations (5) 5
hematology, oncology and palliative medicine (5) 5
induction (5) 5
mast cell disease (5) 5
mast cell leukemia (5) 5
molecular targeted therapy (5) 5
normal cytogenetics (5) 5
phosphorylation (5) 5
prognosis (5) 5
protein kinase inhibitors - pharmacology (5) 5
recurrence (5) 5
staurosporine - pharmacokinetics (5) 5
staurosporine - pharmacology (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
American Journal of Hematology, ISSN 0361-8609, 04/2015, Volume 90, Issue 4, pp. 276 - 281
Journal Article
Clinical & Experimental Allergy, ISSN 0954-7894, 11/2009, Volume 39, Issue 11, pp. 1711 - 1720
Journal Article
Expert Review of Hematology, ISSN 1747-4086, 12/2017, Volume 10, Issue 12, pp. 1033 - 1045
Introduction: Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with inadequate treatment options. Approximately one-third of cases have a... 
AML | Midostaurin | targeted therapy | acute myeloid leukemia | FLT3 | PKC412 | INTERNAL TANDEM DUPLICATION | WILD-TYPE | YOUNGER ADULTS | RISK MYELODYSPLASTIC SYNDROME | OLDER PATIENTS | TYROSINE KINASE INHIBITOR | HIGH-DOSE DAUNORUBICIN | STEM-CELL TRANSPLANTATION | HEMATOLOGY | PHASE-I | CYTOGENETICALLY NORMAL AML
Journal Article
International Journal of Clinical and Experimental Pathology, ISSN 1936-2625, 2014, Volume 7, Issue 6, pp. 3439 - 3443
Journal Article
Journal Article
Journal Article
PHARMACOTHERAPY, ISSN 0277-0008, 12/2017, Volume 37, Issue 12, pp. 1586 - 1599
Acute myeloid leukemia (AML), a clonal hematologic malignancy that results in bone marrow failure, is the most common acute leukemia in adults (median age of... 
midostaurin | acute myeloid leukemia | FLT3-mutant AML | PHARMACOLOGY & PHARMACY | tyrosine kinase inhibitor | PKC412
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 8, pp. 1061 - 1075
Journal Article
Haematologica, ISSN 0390-6078, 10/2018, Volume 103, Issue 11, pp. 1760 - 1771
Mastocytosis is a term used to denote a group of rare diseases characterized by an abnormal accumulation of neoplastic mast cells in various tissues and... 
DASATINIB BMS-354825 | WILD-TYPE | GEMTUZUMAB OZOGAMICIN | ACTIVATING MUTATION | MIDOSTAURIN PKC412 | C-KIT MUTATION | TYROSINE KINASE INHIBITOR | MYELOID-LEUKEMIA | HUMAN MAST-CELLS | HEMATOLOGY | BONE-MARROW LESIONS | Review
Journal Article
Leukemia, ISSN 0887-6924, 2012, Volume 26, Issue 9, pp. 2061 - 2068
Journal Article
PHARMACOTHERAPY, ISSN 0277-0008, 12/2017, Volume 37, Issue 12, pp. E124 - E124
Acute myeloid leukemia (AML), a clonal hematologic malignancy that results in bone marrow failure, is the most common acute leukemia in adults (median age of... 
midostaurin | acute myeloid leukemia | FLT3-mutant AML | PHARMACOLOGY & PHARMACY | tyrosine kinase inhibitor | PKC412
Journal Article
CHIMIA, ISSN 0009-4293, 08/2019, Volume 73, Issue 7-8, pp. 561 - 570
The efficacy and side-effects of drugs do not just reflect the biochemical and pharmacodynamic properties of the parent compound, but often comprise of... 
Nilotinib | Imatinib | Metabolite | SAFETY | Midostaurin | PROTEIN-KINASE INHIBITOR | ACUTE MYELOID-LEUKEMIA | ABL | CHEMISTRY, MULTIDISCIPLINARY | DISCOVERY | PKC412 | Leukaemia | STRUCTURAL BIOLOGY | PHARMACOKINETICS | DRUG METABOLITES
Journal Article
Critical Reviews in Oncology / Hematology, ISSN 1040-8428, 09/2019, Volume 141, pp. 125 - 138
Journal Article
European Journal of Medicinal Chemistry, ISSN 0223-5234, 09/2019, Volume 178, pp. 468 - 483
Journal Article